604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Therapeutic effect of menin inhibitors is reversible in AML treatment and could be enhanced by the targeting of differentiation associated chromatin complex

LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring

Synergistic targeting of KMT2A rearranged AML with combined LSD1 and menin inhibitors

MRC2 A tumor restricted surface antigen for immunotherapy in Acute Myeloid Leukemia

Selinexor enhances the effect of venetoclax on Acute Myeloid Leukemia stem and progenitor cells by disrupting lysosomal function

Aberrant activation of clpp exerts multifaceted anti AML activity beyond tumor cells

Sphingosine 1 phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3 ITD and NRAS mutations through sphingosine kinase 1 AKT pathway downregulation

Mechanisms of chemotherapy resistance driven by Mecom overexpression

BT1 A CD84 targeting T cell engager for selective eradication of leukemic stem cells in Acute Myeloid Leukemia

Butyrate up regulates the expression of CDKN1A to block the cell cycle and inhibits the PI3K AKT signaling pathway to promote apoptosis to play an anti Acute Myeloid Leukemia role

Targeting metabolic vulnerabilities in Acute Myeloid Leukemia Therapeutic potential of l asparaginase and synergy with venetoclax

PARP inhibition by talazoparib results in leukemia cell death via induction of myeloid differentiation

Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro survival pathways and induces deep and durable remission In Vivo

Extracellular arginine deprivation enhances venetoclax sensitivity in acute myeloidleukemia via mitochondrial fission impairment and apoptotic priming

Synergistic efficacy of EZH2 inhibitor combined with new flavonoid derivatives in AML patient derived xenograft mouse models

CSF1R CSF1 axis blockade with axatilimab effectively targets leukemia stem cells and monocytes in AML resistant to BH3 mimetics

INCB160058 selectively targets JAK2V617F driven hematopoiesis in diverse and drug resistant models of myeloproliferative neoplasms

ZBTB7A modulates response to BCL 2 inhibition by venetoclax in acute myeloid leukemia AML

Overcoming midostaurin resistance via dual MYC and GSPT1 degradation by the protac GT19715 in FLT3 amplified AML cells

Cytoplasmic localization of qki mediates therapeutic resistance and immune evasion

Identifying epigenetic vulnerabilities for treatment of HMA refractory myeloid leukemia

PTEN loss reprograms lipid metabolism to modulate venetoclax resistance in acute myeloid leukemia

Cardio safe degrader CT 03p degrades MCL 1 and overcomes venetoclax resistance in AML

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia